CCNG2 and central nervous system cancer: We found that CCNG2 was high expression in 67% (8/12) of WHO I, 68% (13/19) of WHO II gliomas, 18% (3/17) of WHO III, and 21% (3/14) of WHO IV gliomas, indicating a loss of CCNG2 in 81% of high-grade gliomas (Table 1).